IPA enhances H3K27 acetylation at the Tcf7 super-enhancer, driving CD8+ T cell differentiation toward Tpex cells and improving immune checkpoint inhibitor efficacy in melanoma, breast cancer, and CRC (376). The gene discussed is CD8A; the disease is melanoma.